Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
BIOMARKER:
MAP2K1 mutation
i
Other names:
MAP2K1, MAPKK1, MEK1, PRKMK1, Mitogen-activated protein kinase kinase 1
Associations
(9)
News
Trials
C3 | Sensitive
C4 | Sensitive
D | Sensitive
C3 | Resistant
C4 | Resistant
D | Resistant
Show legend
Include preclinical:
Drug categories
Tyrosine Kinase Inhibitors
Immune Checkpoint Inhibitors
Immunotherapy
Threonine-Tyrosine Kinase Inhibitors
CD Protein Inhibitors
Serine-Threonine Kinase Inhibitors
Cancel
Melanoma
Biliary Tract Cancer
Lung Non-Squamous Non-Small Cell Cancer
Pancreatic Ductal Adenocarcinoma
Ovarian Cancer
Non Small Cell Lung Cancer
selumetinib
C4
MAP2K1 mutation
|
Ovarian Cancer
|
selumetinib
trametinib
D
MAP2K1 mutation
|
Melanoma
|
trametinib
C3
MAP2K1 mutation
|
Biliary Tract Cancer
|
trametinib
binimetinib
C3
MAP2K1 mutation
|
Lung Non-Squamous Non-Small Cell Cancer
|
binimetinib
avelumab + binimetinib
C3
MAP2K1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib
DS03090629
D
MAP2K1 mutation
|
Melanoma
|
DS03090629
CTLA4 inhibitor
C3
MAP2K1 mutation
|
Melanoma
|
CTLA4 inhibitor
dabrafenib
D
MAP2K1 mutation
|
Melanoma
|
dabrafenib
lorlatinib
C3
MAP2K1 mutation
|
Non Small Cell Lung Cancer
|
lorlatinib
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
